Global Blood Therapeutics, Inc. (NASDAQ:GBT) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
On May 1, 2017, Global Blood Therapeutics, Inc. announced its
financial results for the three months ended March 31, 2017. The
full text of the press release issued in connection with the
announcement is furnished as Exhibit 99.1 to this Current Report
on Form 8-K.
The information in Item 2.02 of this Form 8-K (including Exhibit
99.1) shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities of that section, nor shall it be deemed
incorporated by reference under the Securities Act of 1933, as
amended, except as expressly set forth by specific reference in
such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description |
| 99.1 | Press Release, dated May 1, 2017, furnished herewith |
About Global Blood Therapeutics, Inc. (NASDAQ:GBT)
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company’s segment is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. It is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD) and is evaluating GBT440 in SCD subjects in an ongoing Phase I/II clinical trial. SCD is a genetic disease marked by red blood cell (RBC) destruction and occluded blood flow and hypoxia, leading to anemia, stroke, multi-organ failure, severe pain crises, and shortened patient life span. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. It is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). Global Blood Therapeutics, Inc. (NASDAQ:GBT) Recent Trading Information
Global Blood Therapeutics, Inc. (NASDAQ:GBT) closed its last trading session up +1.80 at 30.75 with 429,115 shares trading hands.
